To develop a new glucuronide probe for micro-positron emission topography (PET) that can depict ␤-glucuronidase (␤G)-expressing tumors in vivo.
E
nzymes that are selectively expressed at or targeted to tumor sites can be used to convert relatively nontoxic prodrugs into active, cytotoxic drugs to enhance antitumor activity and reduce systemic toxicity, compared with conventional chemotherapy. ␤-Glucuronidase (␤G) is an attractive enzyme for activation of antineoplastic prodrugs. Glucuronide prodrugs of several anticancer drugs have been synthesized, including doxorubicin (1,2), etoposide (3), camptothecin analogs (4, 5) , paclitaxel (6) , docetaxel (7) and alkylating agents (8, 9) . In fact, glucuronide derivatives of almost any antineoplastic agent can be synthesized by using linkers between a drug and a glucuronide group (5, 7) . Glucuronide prodrugs are relatively nontoxic due to the hydrophilic nature of the glucuronide group, which prevents them from entering cells and, thus, from contacting lysosomal ␤G (10) . In addition, glucuronide prodrugs have been shown to produce potent antitumor activity in antibody-directed enzyme prodrug therapy (8, 11) , gene-directed enzyme prodrug therapy (12) (13) (14) , bacterially directed prodrug therapy (15) , as well as directly in prodrug monotherapy (4, 16) , which relies on the presence of elevated levels of ␤G in the tumor interstitial space (16, 17) .
Endogenous ␤G activity in tumors varies widely (18, 19) . In addition, accumulation of targeted or expressed ␤G in tumors may change over time. The ability to image intratumoral ␤G activity in tumors will greatly aid in the design of personalized glucuronide prodrug treatment and greatly improve ␤G-based targeted therapy. However, current ␤G probes are only suitable for in vitro studies but not yet available for in vivo imaging of ␤G activity (20) (21) (22) (23) (24) . To be clinically useful, development of glucuronide probes for more sensitive imaging technologies such as positron emission tomography (PET) will aid in the imaging of ␤G activity in vivo for glucuronide prodrug therapy.
Our purpose in this study was to develop a new glucuronide probe for micro-PET imaging that can depict ␤G-expressing tumors in vivo.
Materials and Methods

Cells and Animals
CT26 murine colon carcinoma and ␤G-expressing CT26 (CT26/␤G) cells (24) were cultured in Dulbecco's Minimal Essential Medium (DMEM) (Sigma-Aldrich, St Louis, Mo) supplemented with 10% heat-inactivated bovine calf serum, 100 U/mL penicillin, and 100 g/mL streptomycin at 37°C in a 5% CO 2 atmosphere. Female BALB/c mice, 6 -8 weeks old, were purchased from the National Laboratory Animal Center (Taipei, Taiwan). To avoid excessive uptake of the radioiodinated agents by the thyroid glands, all mice were pretreated with 0.2% Lugol solution (Sigma-Aldrich) in their drinking water for 2 days prior to the injection of the radioiodinated probes, as previously described (25) . The animal experiments were conducted in accordance with the standards set forth by the National Yang-Ming University Institutional Animal Care and Use Committee. I-PTH-G (370 kBq of solution per well) in 0.5-mL serum-free DMEM at 37°C. Samples were periodically removed at 15, 30, 60, 120, and 240 minutes, were blotted onto an aluminum sheet precoated with silica, and were dried. In Vivo Micro-PET Imaging BALB/c mice (n ϭ 3) bearing established CT26 and ␤G-expressing CT26 tumors (200 -300 mm 3 ) in their left and right chest regions, respectively, were anesthetized with halothane vapor by using a vaporizer system and then were intravenously injected with 3700 kBq (in 100 L)
Generation of 131 I-or 124 I-PTH-G Probes
124 I-PTH-G. To test the specificity of 124 I-PTH-G in vivo, D-saccharic acid 1,4-lactone monohydrate (1 g per kilogram of body weight) was intraperitoneally injected into the mice (n ϭ 3) 1 hour before 124 I-PTH-G injection. PET imaging was sequentially performed at 1, 3, and 20 hours. The tumor-bearing mice were positioned in a micro-PET scanner (R4; Concorde Microsystems, Knoxville, Tenn) with their long axis parallel to the transaxial plane of the scanner. The scanner has a computer-controlled bed with a 10.8-cm transaxial and 8-cm axial field of view. It has no septa and operates exclusively in a three-dimensional list mode. All raw data were first sorted into three-dimensional sinograms, followed by Fourier rebinning and ordered-subsets expectation maximization image reconstruction. Fully three-dimensional list-mode data were collected by using an energy window of 350 -750 keV and a time window of 6 nsec. Image pixel size was 0.85 mm transaxially, with a 1.21-mm section thickness (SCT., K.H.C., I.H.H., and H.E.W., with 2, 4, 2, and 20 years of experience in imaging studies).
Whole-Body Autoradiography in Mice
For autoradiography, the tumor-bearing mice (n ϭ 3) were intravenously injected with 3700 kBq (100 L) of 131 I-PTH-G. Animals were sacrificed by means of chloroform inhalation 3 hours after injection and were immediately dipped into isopentane (Nacalai Tesque, Kyoto, Japan), which was prechilled at liquid nitrogen temperature. The whole carcass was frozen for 1-2 minutes, depending on body size. The frozen carcass was then embedded on a cryostat holder with 4% carboxylmethylcellulose (27) . Coronal sectioning was performed with a slice thickness of 30 m. Slices attached on the microscopic slides were air dried at room temperature, applied to the imaging plates (BAS cassette 2040; Fujifilm, Tokyo, Japan), and exposed for about 36 hours. After exposure, the imaging plates were assayed with a FLA5000 reader (Fujifilm) to acquire the phosphor images. 
Statistical Analysis
The radioactivity of the CT26/␤G tumors and parental CT26 tumors was recorded in the biodistribution analysis. Differences in radioactivity between CT26/␤G and CT26 tumors located on the same mouse were analyzed (SCT., S.R., and T.L.C., with 4, 28, and 18 years experience of data analysis) by using the Wilcoxon signed rank test. P values of less than .05 were considered to indicate a statistically significant difference.
Results
Specific Conversion of PTH-G into PTH by ␤G-expressing Cells in Vitro and ex Vivo
In ␤G-expressing CT26 cells, ␤G is tethered to the surface of CT26 cells to allow free access of hydrophilic PTH-G molecules to the enzyme (Fig 1) (24) . A reddish-brown PTH precipitate was apparent on the CT26/␤G cells and tumors but not on parental CT26 cells and/or tumors after addition of PTH-G (Fig 2) .
Specificity and Half-Life of the Iodinated PTH-G Probes
The percentage of 131 I-PTH-G steadily decreased over time, while the percentage of 131 I-PTH increased, which indicates specific conversion of 131 I-PTH-G to 131 I-PTH by ␤G (Fig 3) . On the contrary, parental CT26 cells barely hydrolyzed 131 I-PTH-G to 131 I-PTH. Cell-associated radioactivity steadily increased in CT26/␤G cells but not in parental CT26 cells (Fig 3b) . D-saccharic acid 1,4-lactone monohydrate hampered the accumulation of cell-associated radioactivity in CT26/␤G cells, indicating that the conversion of 124 I-PTH-G to 124 I-PTH was blocked by inhibition of ␤G activity.
131 I-PTH-G concentration in serum followed a two-phase exponential decay kinetics, with an initial half-life of 11.1 minutes Ϯ 4.3 (standard error) and a terminal half-life of 580 minutes Ϯ 100 (Fig 3c) .
Micro-PET Imaging of ␤G-expressing
Tumors in Vivo 124 I-PTH-G selectively accumulated in CT26/␤G tumors as early as 1 hour after injection (Fig 4a) , suggesting that 124 I-PTH-G was preferentially converted into 124 I-PTH by the CT26/␤G tumors. CT26 tumors, on the other hand, produced weak but distinct signals on micro-PET images. The region of interest ratio of CT26/␤G to parental CT26 tumors was 3.9, 3.5, and 3 at 1, 3, and 20 hours, respectively. We also found strong signals in the abdomen of the mice (Fig 4) . Although radioactivity selectively accumulated in CT26/␤G tumors in mice pretreated with phosphate-buffered saline, D-saccharic acid 1,4-lactone monohydrate completely blocked the generation and accumulation of radioactivity in CT26/␤G tumors (Fig 4b) .
Biodistribution of 131 I-PTH-G in Vivo
Substantial radioactivity accumulated in CT26/␤G tumors (Fig 5) . We also found weaker but distinctive signals in CT26 tumors. Autoradiography and ␤G enzymatic activity matched in the necrotic areas in CT26 tumors as determined at histologic examination (Fig 5, bottom  panel) . We also found strong signals in the internal organs, notably in the gallbladder, liver, and intestines (Fig 5, top  panel) . Mean radioactivity was significantly higher in CT26/␤G tumors than in the parental CT26 tumors at 3 and 20 hours after injection of 131 I-PTH-G (P ϭ .11 at 1 hour, P ϭ .04 at 3 hours, P ϭ .03 at 20 hours, Fig 6) . On average, CT26/␤G tumors accumulated 3.6-, 3.4-, and 3.3-fold more radioactivity than did parental CT26 tumors at 1, 3, and 20 hours, respectively. In contrast, injection of 131 I-PTH did not result in differential accumulation of radioactivity (P ϭ .827 at 1 hour, P ϭ .827 at 3 hours, P ϭ .275 at 20 hours) (Fig 6b) . As in the micro-PET studies, we found strong signals in the gallbladder, liver, and intestines.
Discussion
We have developed a strategy for the micro-PET imaging of ␤G activity based on the hydrophobic conversion of 124 I-PTH-G to 124 I-PTH. Our results show that CT26/␤G cells and tumors selectively hydrolyzed and accumulated PTH-G and 124 I-PTH-G. The micro-PET images demonstrated enhanced activity in CT26/␤G tumors. By using the ␤G-specific inhibitor D-saccharic acid 1,4-lactone monohydrate, we further validated that 124 I-PTH-G is a specific probe for ␤G activity in vitro and in vivo. The biodistribution of 131 I-PTH-G confirmed the preferential accumulation of 131 I-PTH in ␤G-expressing tumors. These results indicate that this method may potentially be a useful diagnostic tool for the detection of ␤G-expressing tumors to personalize glucuronide prodrug monotherapy or targeted therapy.
We noted radioactive signals in the CT26 tumors, gallbladder, and intestines.
In the CT26 tumors, the radioactive signals were most likely generated by ␤G within the necrotic regions, which are known to contain high concentration of I-PTH-G was instead generated by other body sites and then traveled to CT26 tumors, one would expect a more homogeneous signal distribution within the tumors. This prediction, however, is not supported by our data. On the other hand, signals in gallbladder and intestines most likely resulted from excretion of glucuronide metabolites. Liver cells can uptake glucuronide conjugates such as 124 I-PTH-G from the blood by organic anion-transporting polypeptides expressed on the basolateral (sinusoidal) side of liver cells (28, 29) . For example, estradiol-17-␤-D-glucuronide and telmisartan acylglucuronide are substrates for liver uptake by organic aniontransporting polypeptide family members (30) (31) (32) . Once the glucuronide conjugates are within liver cells, Mrp2 (multiple resistance-associated protein 2) expressed on the apical (canicular) side of liver cells then pumps out glucuronide conjugates via the bile duct to the intestine (33) . Anticancer drug metabolites, such as SN-38 glucuronide (a camptothecin derivative) and flavopiridol glucuronide, are secreted into the bile through the action of Mrp2 (34, 35) . ␤G in commensal flora present in the intestinal tract can hydrolyze glucuronide conjugates into their original forms. This is the mechanism underlying the severe diarrhea observed in cancer patients receiving CPT-11 (36) . ond, PTH-G excretion may be shunted from the biliary to the urinary pathway. Repeated administration of acetaminophen can increase expression of Mrp3 and drive the elimination of xenobiotic glucuronides through the urinary pathway (37) . Likewise, probenecid can inhibit Mrp2 and reduce biliary excretion of glucuronides (34, 38) . Increased urinary elimination may reduce the radioactivity retained in the intestines. Last, since PTH-G is likely excreted through the biliary pathway (39) , PTH can be replaced with other compounds that exhibit predominately urinary excretion. In this regard, the relatively hydrophobic chelating agent tetraazacyclododecane tetraacetic acid (DOTA) is efficiently removed from the blood via the kidneys (40) . Gallium 68 -DOTA has been developed for cancer imaging with use of PET (41), which suggests that DOTA is an attractive candidate substitute for PTH.
Selective hydrolysis of a glucuronide probe to a hydrophobic reporter for PET imaging may be an effective strategy to detect ␤G activity in vivo. Conjugation of glucuronide groups usually increases the hydrophilicity of compounds (42, 43) . In addition, although ␤G is highly specific for the glucuronyl residue of glucuronide conjugates, it has little specificity for the conjugated aglycone (44), suggesting that a wide variety of glucuronide-imaging probes could be designed for PET, single photon emission computed tomography (SPECT), or magnetic resonance (MR) imaging. For example, a range of phenolic compounds, such resveratrols, could be glucuronidated and labeled with 124 I to form PET probes with unique properties. Similarly, glucuronide groups can be attached to hydrophobic derivatives of chelating agents such as DOTA for imaging (45) . DOTA-glucuronide derivatives could chelate gadolinium or indium 111 to form imaging probes for the detection of ␤G activity by using MR imaging or SPECT, respectively. Thus, the concept of ␤G-specific conversion and accumulation of hydrophobic probes opens a new venue for the design of ␤G-detecting probes for imaging technologies commonly used in modern medicine.
Two limitations are associated with the current study. First, our method might be inappropriate for the in vivo imaging of ␤G-expressing tumors that reside near the gallbladder and intestines, since these organs display strong signals after injection of the radioiodinated probes. Although some preventive manipulations are suggested, their efficacy remains to be verified. Second, the small sample size has rendered data interpretation difficult. For example, although retention of radioactivity in CT26 versus CT26/␤G tumors at 1 hour after injection is visually different, it was not statistically significant. Future
Figure 6
Figure 6: Graphs show biodistribution of (a)
131 I-PTH-G and (b) 131 I-PTH in selected organs in mice bearing CT26/␤G or parental CT26 tumors. Selected organs and tumors were removed from the mice after 1 (n ϭ 3), 3 (n ϭ 5), and 20 (n ϭ 6) hours. Error bars ϭ standard error of the mean. ‫ء‬ ϭ P Ͻ .05, n.s. ϭ nonsignificant.
MOLECULAR IMAGING: Micro-PET Imaging of ␤-Glucuronidase Activity
Tzou et al studies with larger sample sizes may clarify this issue. In summary, molecular imaging is a promising method to pair diagnosis and therapy for personalized medicine, which is especially useful in cancer therapy because of the many different molecular mechanisms that can cause this disease. We have developed a 124 I-PTH-G probe for micro-PET imaging of ␤G activity by the specific conversion and accumulation of hydrophobic 124 I-PTH in ␤G-expressing tumor sites. Importantly, our strategy is designed for the PET imaging system, which is currently the state-ofthe-art technology in tumor detection. Thus, the development of new glucuronide PET probes should complement the detection capability that can diagnose ␤G-expressing cancers. Successful development of proactive glucuronide probes is expected to pair the diagnosis of ␤G activity and glucuronide prodrug targeted therapy for improved personalized health care.
